Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231303 | 0.90 | — | — | |
| Propane SCHEMBL1390068 | 0.85 | TSHR (0.50) | HIF1ATSHRLMNAFAAHTRPV1 | |
| SCHEMBL1409410 | 0.82 | — | — | |
| SCHEMBL28922962 | 0.81 | LMNA (0.59) | HIF1ATSHRLMNAFAAHTRPV1 | |
| SCHEMBL585190 | 0.81 | LMNA (0.59) | HIF1ATSHRLMNAFAAHTRPV1 | |
| SCHEMBL294142 | 0.80 | TSHR (0.52) | HIF1ATSHRLMNAFAAHTRPV1 | |
| SCHEMBL15327039 | 0.80 | TSHR (0.52) | HIF1ATSHRLMNAFAAHTRPV1 | |
| SCHEMBL293702 | 0.80 | TSHR (0.52) | HIF1ATSHRLMNAFAAHTRPV1 | |
| SCHEMBL2523320 | 0.80 | TSHR (0.52) | HIF1ATSHRLMNAFAAHTRPV1 | |
| SCHEMBL21619221 | 0.80 | TSHR (0.52) | HIF1ATSHRLMNAFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132689-A1 | Complexing using an ortho carboxy acetal; biodrug delivery | ROCHE MADISON INC | 2008-06-05 | — | — | US | disclosed |
| US-7348453-B2 | Labile linkage for compound delivery to a cell | MIRUS BIO CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2005026253-A2 | LABILE LINKAGE FOR COMPOUND DELIVERY TO A CELL | MIRUS BIO CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054604-A1 | Labile linkage for compound delivery to a cell | ROCHE MADISON INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054604-A1 | Labile linkage for compound delivery to a cell | AADAC, PAICS, FURIN | HIF1A 1863/4885TSHR 4180/4885LMNA 1044/4885 |
| US-20080132689-A1 | Complexing using an ortho carboxy acetal; biodrug delivery | CEL, PAICS, OGA | HIF1A 2647/4885TSHR 3816/4885LMNA 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.